Primary |
Prothrombin Time Prolonged |
17.9% |
Anaemia |
10.7% |
Coagulopathy |
10.7% |
Transfusion-related Acute Lung Injury |
10.7% |
Anticoagulant Therapy |
7.1% |
Blood Product Transfusion |
7.1% |
Gastrointestinal Haemorrhage |
7.1% |
Haemorrhage |
7.1% |
Activated Partial Thromboplastin Time Prolonged |
3.6% |
Haemoglobin Decreased |
3.6% |
Procoagulant Therapy |
3.6% |
Renal Failure |
3.6% |
Thrombosis |
3.6% |
Thrombotic Thrombocytopenic Purpura |
3.6% |
|
Transfusion-related Acute Lung Injury |
42.4% |
Pulmonary Oedema |
12.1% |
Lung Infiltration |
6.1% |
Wheezing |
6.1% |
Acute Respiratory Failure |
3.0% |
Blood Product Transfusion |
3.0% |
Cardiac Failure |
3.0% |
Feeling Abnormal |
3.0% |
Pleural Effusion |
3.0% |
Respiratory Disorder |
3.0% |
Respiratory Distress |
3.0% |
Transfusion Reaction |
3.0% |
Transfusion Related Complication |
3.0% |
Transfusion-related Circulatory Overload |
3.0% |
Virus Serology Test Positive |
3.0% |
|
Secondary |
Shock Haemorrhagic |
16.9% |
Haemorrhagic Disorder |
9.0% |
Renal Transplant |
8.6% |
Sedation |
6.8% |
Drug Use For Unknown Indication |
4.5% |
Immunosuppression |
4.5% |
Infection |
4.5% |
Acute Myeloid Leukaemia |
3.8% |
Coagulopathy |
3.8% |
Haemolytic Uraemic Syndrome |
3.8% |
Hepatic Failure |
3.8% |
Product Used For Unknown Indication |
3.8% |
Blood Product Transfusion |
3.4% |
Gastroenteritis |
3.4% |
Influenza Like Illness |
3.4% |
Lymph Node Pain |
3.4% |
Lymphadenopathy |
3.4% |
Procedural Haemorrhage |
3.4% |
Cerebral Haemorrhage |
3.0% |
Ischaemic Stroke |
3.0% |
|
Hepatitis B |
13.0% |
Ventricular Tachycardia |
11.1% |
Hepatitis C |
9.3% |
Transmission Of An Infectious Agent Via A Medicinal Product |
9.3% |
Pulmonary Oedema |
7.4% |
Transfusion-related Acute Lung Injury |
7.4% |
Lymphadenopathy |
5.6% |
Tongue Oedema |
5.6% |
Haemorrhage |
3.7% |
Hepatitis Post Transfusion |
3.7% |
Loss Of Consciousness |
3.7% |
Transfusion-related Circulatory Overload |
3.7% |
Viral Myocarditis |
3.7% |
Anaphylactic Shock |
1.9% |
Bile Duct Stone |
1.9% |
Blood Product Transfusion |
1.9% |
Bronchospasm |
1.9% |
Deep Vein Thrombosis |
1.9% |
Disseminated Intravascular Coagulation |
1.9% |
Hepatitis Fulminant |
1.9% |
|
Concomitant |
Product Used For Unknown Indication |
34.7% |
Drug Use For Unknown Indication |
12.8% |
Coronary Artery Bypass |
10.9% |
Aortic Valve Replacement |
4.4% |
Prophylaxis |
3.8% |
Infection Prophylaxis |
3.5% |
Catheterisation Cardiac |
3.5% |
Coagulopathy |
3.3% |
Mitral Valve Replacement |
3.2% |
Haemorrhage |
2.8% |
Acute Myeloid Leukaemia |
2.3% |
Gastric Cancer |
2.2% |
Hypertension |
1.8% |
Thrombocytopenia |
1.7% |
Disseminated Intravascular Coagulation |
1.6% |
Ill-defined Disorder |
1.5% |
Intra-aortic Balloon Placement |
1.5% |
Nausea |
1.4% |
Surgery |
1.4% |
Tricuspid Valve Repair |
1.4% |
|
Pain |
12.5% |
Injury |
11.7% |
Unevaluable Event |
8.5% |
Anhedonia |
7.3% |
Fear |
7.0% |
Renal Failure |
7.0% |
Anxiety |
5.2% |
Sepsis |
5.2% |
Multi-organ Failure |
4.6% |
Renal Impairment |
4.4% |
Emotional Distress |
3.7% |
Stress |
3.6% |
Renal Failure Acute |
3.3% |
Upper Gastrointestinal Haemorrhage |
3.3% |
Death |
3.0% |
Renal Injury |
2.5% |
Depression |
2.0% |
Drug Ineffective |
1.9% |
Septic Shock |
1.7% |
White Blood Cell Count Decreased |
1.7% |
|